ArticleJournal of viral hepatitis2016
A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy.
Article in Journal of viral hepatitis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 56 citations in OpenAlex.
- Article
- Rationale, design, and methodology of a randomized controlled trial evaluating the impact of peer-enhanced care coordination on linkage to HCV care among formerly incarcerated individuals.Contemporary clinical trials · 2025Article
- Linkages between incarceration and health for older adults.Health & justice · 2025Review
- Barriers and advocacy needs for hepatitis C services in prisons: Informing the prisons hepatitis C advocacy toolkit.The International journal on drug policy · 2024Article
- Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination.Journal of viral hepatitis · 2023Article
- Hepatitis C Screening and Treatment Program in Hungarian Prisons in the Era of Direct Acting Antiviral Agents.Viruses · 2022Article
- Quick diagnosis, staging, and treatment of HCV infection among people living in prison: Opinion expert panel.Frontiers in public health · 2022Article
- Prevalence of Hepatitis in Prisoners: A Systematic Review of Current Evidence.Infectious disorders drug targets · 2022Article
- Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir.Infectious diseases and therapy · 2021Article
- The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients.Clinical and molecular hepatology · 2021Article
- The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases.Harm reduction journal · 2021Article
- New hepatitis C virus infection, re-infection and associated risk behaviour in male Irish prisoners: a cohort study, 2019.Archives of public health = Archives belges de sante publique · 2021Article
- Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.The lancet. Gastroenterology & hepatology · 2021Review
- Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era.Harm reduction journal · 2020Article
- The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014-2017.EClinicalMedicine · 2020Article
- Hepatitis C in the criminal justice system: opportunities for global action in the era of viral hepatitis elimination.BMC medicine · 2020Article
- Microelimination of Chronic Hepatitis C by Universal Screening Plus Direct-Acting Antivirals for Incarcerated Persons in Taiwan.Open forum infectious diseases · 2020Article
- Outcomes of Hepatitis C Virus Treatment in the New York City Jail Population: Successes and Challenges Facing Scale up of Care.Open forum infectious diseases · 2020Article
- Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination.Current HIV/AIDS reports · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 11 institutions in 2 countries.
Funding
Abstract
Prisoners are a priority group for hepatitis C (HCV) treatment. Although treatment durations will become shorter using directly acting antivirals (DAAs), nearly half of prison sentences in Scotland are too short to allow completion of DAA therapy prior to release. The purpose of this study was to compare treatment outcomes between prison- and community-based patients and to examine the impact of prison release or transfer during therapy. A national database was used to compare treatment outcomes between prison treatment initiates and a matched community sample. Additional data were collected to investigate the impact of release or transfer on treatment outcomes. Treatment-naïve patients infected with genotype 1/2/3/4 and treated between 2009 and 2012 were eligible for inclusion. 291 prison initiates were matched with 1137 community initiates: SVRs were 61% (95% CI 55%-66%) and 63% (95% CI 60%-66%), respectively. Odds of achieving a SVR were not significantly associated with prisoner status (P=.33). SVRs were 74% (95% CI 65%-81%), 59% (95% CI 42%-75%) and 45% (95% CI 29%-62%) among those not released or transferred, transferred during treatment, or released during treatment, respectively. Odds of achieving a SVR were significantly associated with release (P<.01), but not transfer (P=.18). Prison-based HCV treatment achieves similar outcomes to community-based treatment, with those not released or transferred during treatment doing particularly well. Transfer or release during therapy should be avoided whenever possible, using anticipatory planning and medical holds where appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.